Background-Angiotensin II (Ang II) has diverse actions on cardiac electrical activity. Little information is available, however, regarding immediate electrophysiological effects of Ang II on cardiac repolarization. Methods and Results-The present study investigated the immediate effects of Ang II on the slow component of delayed rectifier K ϩ current (I Ks ) and action potentials in guinea pig atrial myocytes using the whole-cell patch-clamp technique. Bath application of Ang II increased the amplitude of I Ks (EC 50 , 6.16 nmol/L) concentration dependently. The stable analogue Sar 1 -Ang II was also effective at increasing I Ks . The voltage dependence of I Ks activation and the kinetics of deactivation were not significantly affected by these agonists. The enhancement of I Ks was blocked by the Ang II type 1 (AT 1 ) receptor antagonist valsartan (1 mol/L) and was markedly attenuated by inclusion of GDP␤S (2 mmol/L) in the pipette, indicating an involvement of G protein-coupled AT 1 receptor. The stimulatory effect was also significantly reduced by the phospholipase C inhibitor compound 48/80 (100 mol/L) and the protein kinase C inhibitors bisindolylmaleimide I (200 nmol/L) and H-7 (10 mol/L), suggesting that AT 1 receptor acts through phospholipase C-protein kinase C signaling cascade to potentiate I Ks . As expected from its stimulatory action on I Ks , Sar 1 -Ang II markedly shortened the action potential duration, which could be reversed by valsartan. Conclusions-The potentiation of I Ks via AT 1 stimulation in atrial myocytes, accompanied by a shortening of the action potential duration, suggests a potential mechanism by which elevated levels of Ang II may promote atrial fibrillation in heart failure and warrants further investigation. (Circulation. 2006;113:1278-1286.)
T he renin-angiotensin system (RAS) plays a fundamental role in maintaining cardiovascular homeostasis, and disorders of the RAS are closely related to the development of hypertension, heart failure, atherosclerosis, cardiac hypertrophy, and myocardial and vascular remodeling. [1] [2] [3] [4] [5] An octapeptide angiotensin II (Ang II) is the principal effector of the RAS and produces its potent and diverse biological actions by interacting with specific membrane receptors, namely Ang II type 1 (AT 1 ) and type 2 (AT 2 ) receptors. The AT 1 receptors are widely distributed in a variety of cell and tissue types and mediate most of the known actions of Ang II, whereas the AT 2 receptor is expressed mainly in the embryonic and neonatal states but is upregulated in adult tissues under some pathological conditions. 6 The various biological actions of Ang II via AT 1 receptor can be divided into the short-term effects that occur within minutes and the long-term effects that take place within hours or even later; vascular contraction constitutes the short-term events, whereas the long-term effects include a transcriptional response that leads to mor
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phological and functional alterations of cardiovascular systems such as cardiac hypertrophy, fibrosis, and remodeling. 7 There is increasing evidence that the RAS is also associated with the occurrence of atrial and ventricular arrhythmias in experimental animals, 8, 9 and recent clinical studies have proved that blockade of the RAS with ACE inhibitors or AT 1 antagonists is effective for the treatment of atrial fibrillation (AF). 10, 11 The shortening of action potential duration (APD) and effective refractory period can be regarded as one of the main factors responsible for the occurrence of reentry-based tachyarrhythmias such as AF. Little information is available, however, regarding the effect of Ang II on repolarizing K ϩ currents and resultant changes in APD in cardiac myocytes.
It has been demonstrated in various mammalian species, including humans, that the delayed rectifier K ϩ current (I K ) consists of rapidly and slowly activating components (I Kr and I Ks , respectively), which are the major repolarizing outward currents of atrial and ventricular action potentials. 12 I Kr and I Ks reflect the expression of distinct molecular entities; the pore-forming ␣-subunit KvLQT1 (KCNQ1) coassembles with an accessory ␤ subunit minK (KCNE1) to form the I Ks channels, and the HERG (KCNH2) constitutes the poreforming subunit of the channel that underlies the I Kr channels. Mutations in genes encoding these channel proteins are responsible for the long-QT syndrome in humans, an inherited cardiac arrhythmia characterized by abnormal cardiac repolarization and a high risk for sudden death. 13 I Ks also represents a relevant target for modulation by autonomic neurotransmitters and hormones and thereby mediates the regulation of cardiac electrical activity and contraction by these extracellular signaling molecules.
The present study was designed to examine the possible regulation of I Ks by Ang II and its associated signaling pathways in isolated guinea pig atrial myocytes using the whole-cell patch-clamp technique. Our results show for the first time that Ang II in nanomolar concentrations markedly potentiates I Ks through a mechanism involving activation of the G protein-coupled AT 1 receptor linked to the phospholipase C (PLC)-protein kinase C (PKC) pathway.
Methods

Preparation of Atrial Myocytes
The experimental procedures were conducted in accordance with The Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH publication 85-23, revised 1996). Single atrial myocytes were enzymatically dissociated from the heart of adult Hartley guinea pigs as described previously. 14 
Solutions and Chemicals
Normal Tyrode's solution contained (in mmol/L) 140 NaCl, 5.4 KCl, 1.8 CaCl 2 , 0.5 MgCl 2 , 0.33 NaH 2 PO 4 , 5.5 glucose, and 5.0 HEPES (pH adjusted to 7.4 with NaOH). The standard external solution for measuring I Ks was normal Tyrode's solution supplemented with 0.4 mol/L nisoldipine (a generous gift from Bayer AG, Wuppertal-Elberfeld, Germany) and 5 mol/L E-4031 (Wako, Osaka, Japan). Agents added to the external solution included Ang II (human; Calbiochem, San Diego, Calif, and Sigma, St Louis, Mo), Sar 1 -Ang II (Sigma), 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7, Seikagaku, Tokyo, Japan), bisindolylmaleimide I (Bis I, Sigma), phorbol 12-myristate 13-acetate (PMA; Sigma), 1-oleoyl-2-acetyl-sn-glycerol (OAG; Sigma), KT5720 (Alomone Labs, Jerusalem, Israel), valsartan (a generous gift from Novartis, Basel, Switzerland), and candesartan (a generous gift from Takeda Pharmaceutical Chemical Industries, Osaka, Japan Time courses of changes in the amplitude of I Ks in the presence of various reagents were determined by measuring the amplitude of tail currents elicited on repolarization to a holding potential of Ϫ50 mV after 2000-ms depolarization to 30 mV every 10 or 20 seconds.
Statistical Analysis
All averaged values presented are meanϮSEM. Statistical comparisons were made by Wilcoxon signed-rank test for paired data. Wilcoxon rank-sum test was used to compare unpaired data between 2 groups; the Kruskal-Wallis test was applied to compare data among Ն3 groups. A value of PϽ0.05 was considered statistically significant.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written. Figure 1A and 1B demonstrates the representative examples for the stimulatory effect of Ang II and its stable analogue Sar 1 -Ang II, respectively, on I Ks in guinea pig atrial myocytes. Atrial myocytes were depolarized from a holding potential of Ϫ50 mV to test potentials of Ϫ40 to 50 mV for 2000 ms, before and during exposure to 1 mol/L Ang II ( Figure 1A ) or 100 nmol/L Sar 1 -Ang II ( Figure 1B ). Both Ang II and Sar 1 -Ang II markedly increased the slowly activating outward currents during depolarizations and the decaying tail currents on return to the holding potential, which represented the activation and deactivation of I Ks , respectively. The potentiation of I Ks by Ang II and Sar 1 -Ang II was quantitatively evaluated by measuring the amplitude of tail currents elicited on return to the holding potential after a 2000-ms test pulse to 30 mV. As demonstrated in Figure 1C , 1 mol/L Ang II and 100 nmol/L Sar 1 -Ang II increased the amplitude of I Ks by 60.8Ϯ6.8% (nϭ8) and 100.7Ϯ16.4% (nϭ8), respectively. The percent increase in the amplitude of I Ks tail current thus calculated was plotted against concentrations of Ang II ( Figure 1D ). The mean data could be well described by a Hill equation with an EC 50 of 6.16 nmol/L and n H of 1.50.
Results
Stimulatory Action of Ang II and Sar 1 -Ang II on I Ks in Guinea Pig Atrial Myocytes
We then examined whether Ang II and Sar 1 -Ang II affected the voltage dependence of I Ks activation by measuring the amplitude of tail currents elicited on return to a holding potential of Ϫ50 mV after 2000-ms depolarizing pulses to test potentials of Ϫ40 to 50 mV. Figure 2A illustrates a representative example of I-V relationships for I Ks tail currents recorded before and during exposure to 1 mol/L Ang II obtained from the experiment of Figure 1A . The tail current amplitude at each test potential was then normalized with reference to the maximum value at 50 mV, and mean values for the normalized tail currents, obtained from 6 experiments, were plotted against test potentials ( Figure 2B ). The data points were reasonably well fitted by a Boltzmann equation, with V 1/2 of 10.4Ϯ1.5 mV and k of 11.1Ϯ0.8 mV for control and V 1/2 of 12.2Ϯ2.5 mV and k of 10.3Ϯ1.1 mV for Ang II (nϭ6). Thus, the voltage dependence of I Ks activation was found to be affected little, if at all, by Ang II. In a separate set of experiments, it was also confirmed that Sar 1 -Ang II increased the amplitude of I Ks without appreciably affecting the voltage dependent activation of I Ks (V 1/2 of 10.1Ϯ2.2 mV and k of 11.8Ϯ1.3 mV; nϭ6).
To examine whether the kinetics of I Ks deactivation was affected by Ang II and Sar 1 -Ang II, the tail currents elicited on return to Ϫ50 mV after depolarizing pulses were evaluated by fitting to the sum of 2 exponential functions ( Figure 2C ).
The time constants for the fast ( f ) and slow ( s ) components averaged 69.6Ϯ10.8 and 305.6Ϯ57.6 ms for control, 77.7Ϯ6.2 and 233.0Ϯ31.9 ms for Ang II, and 69.4Ϯ12.0 and 297.2Ϯ71.7 ms (nϭ6) for Sar 1 -Ang II, respectively ( Figure  2D ). There are no significant differences in the values of f and s among control, Ang II, and Sar 1 -Ang II groups, suggesting that the kinetics of current deactivation at Ϫ50 mV was not significantly affected by Ang II and Sar 1 -Ang II.
Signal Transduction Pathways Involved in AT 1 Receptor-Mediated Increase in I Ks
We proceeded to explore the signal transduction pathways mediating the stimulatory action of Ang II and Sar 1 -Ang II on I Ks . To examine whether the I Ks response to Ang II and Sar 1 -Ang II was mediated through the AT 1 receptor, the effect of these agonists on I Ks was examined in the presence of the selective AT 1 receptor antagonist valsartan. 15 As illustrated in Figure 3A , pretreatment of atrial myocytes with 1 mol/L valsartan almost totally prevented the stimulatory action of 100 nmol/L Sar 1 -Ang II on I Ks . In a total of 8 myocytes, Sar 1 -Ang II (100 nmol/L) potentiated I Ks by 15.6Ϯ4.6% in the presence of valsartan (1 mol/L), which is significantly smaller than the degree of the I Ks potentiation in the absence of valsartan (100.7Ϯ16.4% increase; nϭ8, PϽ0.05; Figure 3C) . Similarly, the potentiation of I Ks by 1 mol/L Ang II was almost totally abolished by pre-exposure to 1 mol/L valsartan (control, 60.8Ϯ6.8% increase, nϭ8; valsartan, 8.5Ϯ3.4% increase, nϭ8; PϽ0.05). These observations support the view that the potentiation of I Ks by Ang II and Sar 1 -Ang II is mediated through the AT 1 receptor. Moreover, valsartan alone had minimal effect on baseline I Ks (7.8Ϯ2.9% increase, nϭ7; Figure 3C ), suggesting that valsartan prevents the stimulatory action of Ang II and Sar 1 -Ang II by blocking the binding of these agonists to the AT 1 receptor.
To explore whether the AT 1 receptor is tonically activated to potentiate I Ks in guinea pig atrial myocytes, we examined the effect of candesartan, the inverse agonist of the AT 1 receptor, 16 on I Ks in basal conditions. As demonstrated in Figure 3B and 3C, the baseline I Ks was not appreciably affected by exposure to candesartan at concentrations of 100 nmol/L and 2 mol/L, which suggests that there is little, if any, tonic activation of AT 1 receptor leading to the enhancement of I Ks in baseline conditions of guinea pig atrial myocytes.
It has been demonstrated in various cell types, including guinea pig cardiac myocytes, 7, 17 that the AT 1 receptor is 
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coupled to the activation of PLC via heterotrimeric G proteins, which results in production of inositol 1,4,5-trisphosphate (InsP 3 ), a Ca 2ϩ -mobilizing second messenger, and diacylglycerol (DAG), an activator of PKC. Both an elevation in intracellular free Ca 2ϩ and activation of PKC have been associated with an enhancement of I Ks in guinea pig cardiac myocytes. 18 We therefore tested whether these signaling molecules are involved in an AT 1 receptor-mediated increase in I Ks . Because the stable analogue Sar 1 -Ang II evokes a larger increase in the amplitude of I Ks than Ang II does ( Figure 1C ), we used Sar 1 -Ang II as an agonist at the AT 1 receptor in subsequent experiments.
We examined whether G protein activation is involved in the signal transduction pathway by internally perfusing the nonhydrolysable GDP analogue GDP␤S that irreversibly inhibits G protein activation. As illustrated in Figure 4A , the stimulatory effect of Sar 1 -Ang II on I Ks was greatly reduced in atrial myocytes dialyzed with 2 mmol/L GDP␤S (control, 100.7Ϯ16.4% increase, nϭ8; GDP␤S, 15.9Ϯ7.0% increase, nϭ7; PϽ0.05), indicating that G-protein activation mediates the potentiation of I Ks via AT 1 receptor. As shown in Figure 4B To test whether PKC mediates the I Ks response to AT 1 receptor stimulation, we investigated the effect of PKC inhibitors and activators on the stimulatory action of Sar 1 -Ang II. As illustrated in Figure 5A and 5B, the stimulatory action of Sar 1 -Ang II was largely abolished by pretreatment of atrial myocytes either with the nonspecific PKC inhibitor H-7 (16.0Ϯ9.2% increase, nϭ4) or with the specific PKC inhibitor Bis I (9.8Ϯ6.4% increase, nϭ5). These results strongly suggest that the potentiation of I Ks via the AT 1 receptor involves PKC activation. We also checked whether Sar 1 -Ang II could further increase I Ks after potentiation by maximal PKC activation. In guinea pig atrial myocytes, increasing the concentration of the nonspecific PKC activator PMA above 300 nmol/L produced no further increase in the amplitude of I Ks (data not shown), indicating that a maximal potentiation of I Ks was attained by 300 nmol/L PMA (44.5Ϯ5.6% increase, nϭ4). As illustrated in Figure 5C , Sar 1 -Ang produced little further increase in I Ks that was prestimulated maximally with 300 nmol/L PMA (7.7Ϯ2.3% increase, nϭ7; Figure 5E ). When these reagents were applied in reverse order (first Sar 1 -Ang II and then PMA), there was again only a little further increase in I Ks during exposure to PMA (6.2Ϯ1.0% increase, nϭ5; data not shown). These observations suggest that Sar 1 -Ang II and PMA activated the same signaling pathway to potentiate I Ks . The involvement of PKC activation was supported further by the observation that Sar 1 -Ang II caused only a small additional increase in I Ks after a maximal potentiation by the selective PKC activator OAG at 20 mol/L (Figure 5D ; 10.1Ϯ1.5% increase, nϭ9; Figure 5E ).
To rule out the possible involvement of protein kinase A (PKA) in the AT 1 -evoked potentiation of I Ks , the effect of 
Shortening of APD by AT 1 Receptor Stimulation
Because cardiac repolarization is shaped on a subtle balance of multiple ionic channel activities, an alteration in amplitude of major repolarizing currents such as I Ks would lead to substantial changes in the repolarization process. We therefore examined the net effect of Sar 1 -Ang II on action potentials in guinea pig atrial myocytes during superfusion with normal Tyrode's solution with no added blockers for ionic channels. Figure 7A represents superimposed traces of action potentials recorded before and during exposure to Sar 1 -Ang II (100 nmol/L) and after the agonist was washed out. Sar 1 -Ang II markedly shortened APD, which was almost totally reversed on washing out of the agonist. In a separate set of experiments ( Figure 7B ), we confirmed that the Sar 1 -Ang II (100 nmol/L)-induced shortening of APD was significantly reversed by the subsequently applied valsartan (1 mol/L). In a total of 12 myocytes, APD 90 was reduced from a control value of 113.1Ϯ8.8 to 63.1Ϯ5.8 ms during exposure to Sar 1 -Ang II, which was partially recovered to 88.1Ϯ7.0 ms (nϭ10) by the subsequent application of valsartan ( Figure 7C ). The resting membrane potential (control, Ϫ84Ϯ3 mV; Sar 1 -Ang II, Ϫ83Ϯ2 mV; nϭ8) and action potential amplitude (control, 120Ϯ9 mV; Sar 1 -Ang II, 118Ϯ6 mV; nϭ8) remained unchanged during exposure to Sar 1 -Ang II.
Discussion
The present experiments demonstrate that stimulation of the AT 1 receptor evokes a marked increase in the amplitude of I Ks in guinea pig atrial myocytes. Ang II is effective at potentiating I Ks at concentrations of ՆϷ1 nmol/L ( Figure 1D ), which appears to be higher compared with the plasma level of Ang II in humans at baseline conditions (Ϸ5 pmol/L). 19 However, Ang II is also stored in cardiomyocytes, is secreted by various stimuli such as mechanical stress, and acts as autocrine/paracrine factors. 20 A previous study found that the concentration of Ang II in the interstitial fluid space of dog heart is Ϸ6 nmol/L, 21 which seems to be comparable to the concentration needed to affect I Ks in cardiac myocytes. It has been shown in various tissue and cell types that AT 1 receptors are coupled predominantly to PLC via heterotrimeric G protein Gq, which leads to the hydrolysis of phosphatidylinositol 4,5-bisphosphate to produce InsP 3 and DAG. 7 (Figures 3 and 4) . The involvement of resultant activation of PKC in the action of Ang II is supported by the experiments using the inhibitors and activators of PKC; the stimulatory action of Ang II was greatly reduced by the presence of Bis I and H-7 and was masked by previous application of PMA and OAG ( Figure 5 ). At present, the precise mechanism by which PKC regulates I Ks remains to be fully elucidated. The recent mutagenesis study has detected PKC phosphorylation sites (S409, S464, T513, and S577) in the C-terminus of KCNQ1 protein, responsible for potentiating the KCNQ1/KCNE1 channel, 22 the molecular constituents of human I Ks . 13 However, it is also possible that PKC acts on nonchannel substrate(s) to enhance I Ks . Further studies are thus required to clarify the molecular basis for PKC-mediated regulation of I Ks . Adult guinea pig myocardium has been demonstrated to express the ␣, ␤II, ␥, ⑀, and isoforms of PKC. 23 The observation that I Ks can be readily enhanced not only by PMA and OAG but also by AT 1 stimulation in a strong Ca 2ϩ buffering of the cytoplasm (5 mmol/L EGTA) suggests the possibility that the Ca 2ϩ -independent novel isoform PKC⑀, rather than Ca 2ϩ -dependent conventional PKC isoforms, is preferentially involved in the I Ks response under the present experimental conditions. It has recently been reported that the KCNQ1/KCNE1 channel heterologously expressed in Xenopus oocytes is potentiated by both PKC␤II and PKC⑀. 24 It will be interesting to examine which isoform of PKC mediates the potentiation of I Ks via AT 1 receptors in atrial myocytes.
It was previously demonstrated in guinea pig ventricular myocytes that Ang II decreases I Ks but increases I Kr , 25 which is apparently in contrast to the present results concerning the effect of Ang II on I Ks . One possible explanation could be the different method of dissecting I K into its 2 components, I Kr and I Ks . Consistent with this, our preliminary results showed that Sar 1 -Ang II (100 nmol/L) did not evoke any appreciable inhibitory effect on I Ks in guinea pig ventricular myocytes when evaluated with the present experimental protocol shown in Figure 1 (unpublished observation) . Alternatively, intracellular signaling pathways coupled to the AT 1 receptor might be dissimilar between atrial and ventricular myocytes. It was also shown that in guinea pig hearts, AT 1 receptor in atria has a higher affinity for Ang II than that in ventricles. 26 Previous studies have shown that AF itself causes progressive electrophysiological remodeling (shortening of effective refractory period) in the atria by affecting the expression and function of several ion channels. 27, 28 It has recently been demonstrated that an upregulation of AT 1 receptors, which occurs in the left atrium of patients with lone AF and AF with mitral valve disease, is closely related to the remodeling process and stabilization of AF. 29 Consistent with this notion, it was also reported that electrical remodeling during experimental AF is prevented by the AT 1 antagonist candesartan in dogs. 30 The AT 1 receptor-mediated shortening of APD via potentiation of I Ks (Figure 7 ) might be the another way through which Ang II participates in electrophysiological perturbation in the atria during AF. On the other hand, the present observation that a drastic shortening of atrial APD by AT 1 stimulation can be substantially reversed after addition of the AT 1 antagonist valsartan could explain why the incidence of newly developed AF is decreased in patients (with heart failure) who receive the drug (Val-HeFT trial). 31 It should be noted, however, that a possible direct blockade of repolarizing currents other than I Ks by valsartan could also contribute to the reversal of APD shortening observed in this study ( Figure 7B and 7C) .
In recent years, a prospective, randomized trial has demonstrated that in patients with persistent AF cardioverted to sinus rhythm, adding the AT 1 antagonist irbesartan to amiodarone is more effective in maintaining sinus rhythm compared with treatment with amiodarone alone. 10 In this trial, the benefit of irbesartan is largely ascribed to the reduction of the immediate and so-called subacute (during 1 hour and the first weeks after cardioversion, respectively) recurrences of AF. The immediate reversal of APD shortening by AT 1 blockade (Figure 7 ) may again contribute at least partly to this advantage of irbesartan in preventing relapses of AF in the initial short-term phase.
